| Literature DB >> 31379997 |
Azizeh Asadzadeh1, Hooria Seyedhosseini Ghaheh2, Fatemeh Sholehvar3, Mohammadali Takhshid4, Mohammad Mehdi Naghizadeh5.
Abstract
BACKGROUND: Type 2 Diabetes Mellitus (T2DM) is a serious problem in the world. 5-Hydroxytryptamine (5-HT, serotonin) plays an important role in obesity, glucose control and insulin resistance. The polymorphism of the serotonin transporter gene linked promoter region (5-HTTLPR) might influence 5-HTT expression and serotonin uptake. The polymorphism results in two alleles of L (Long) and S (Short). The aim of the present study was to evaluate the association between 5-HTTLPR genotypes in type 2 diabetes mellitus (T2DM), obesity as well as serum biochemical profiles in Iranian population from 2012 until 2015.Entities:
Keywords: 5-HTT gene; 5-HTTLPR polymorphism; Serotonin; Type 2 diabetes mellitus
Year: 2019 PMID: 31379997 PMCID: PMC6626511
Source DB: PubMed Journal: Avicenna J Med Biotechnol ISSN: 2008-2835
Figure 1.5-HTTLPR genetic polymorphism. Genotypes of 5-HTTLPR polymorphism determined by PCR method and analyzed by a 2.5% agarose gel electrophoresis stained with DNA safe stain and viewed under UV light. The size of the restriction fragments is shown.
Demographic and clinical variables of diabetic and normal control subjects
| 84(46.7%)/96(53.3) | 84(46.7%/96(53.3%) | 1.000 | |
| 62.24±7.51 | 59.89±6.34 | 0.111 | |
| 132.89±11.08 | 149.60±14.22 | <0.001 | |
| 86.70±7.29 | 89.74±7.14 | 0.049 | |
| 26.29±3.21 | 29.01±2.27 | 0.001 | |
| 5.40±0.64 | 7.55±1.18 | <0.001 | |
| 88.67±11.47 | 237.20±59.30 | <0.001 | |
| 172.43±56.49 | 251.53±70.64 | <0.001 | |
| 195.66±61.88 | 285.84±64.72 | <0.001 | |
| 67.42±10.74 | 52.55±15.33 | <0.001 | |
| 128.24±64.50 | 183.57±60.78 | <0.001 |
Data was presented as frequency (percentage) and compared with chi-square test for sex. Also was presented with Mean±SD and compared with t test for other variables. Values of p≤0.05 were considered significant (*). F: Female, M: male, SBP: Systolic Blood Pressure, DPB: Diastolic Blood Pressure, BMI: Body Mass Index, Hb: Hemoglobin, FBS: Fasting Blood Sugar, TG: Triglyceride, Chol: Cholesterol, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein.
The frequency of 5-HTTLPR genotypes and alleles in diabetic and normal control groups
| LL | 76 | 42.2% | 84 | 46.7% | |||
| LS | 80 | 44.4% | 72 | 40.0% | 0.902 | ||
| SS | 24 | 13.3% | 24 | 13.3% | |||
| LL | 76 | 42.2% | 84 | 46.7% | |||
| LS + SS | 104 | 57.8% | 96 | 53.3% | LL | 0.671 | 1.197 (0.790 to 1.815) |
| LS | 80 | 44.4% | 72 | 40.0% | |||
| LL + SS | 100 | 55.6% | 108 | 60.0% | LS | 0.670 | 0.833 (548 to 1.267) |
| SS | 24 | 13.3% | 24 | 13.3% | |||
| LL + LS | 156 | 86.7% | 156 | 86.7% | SS | 1.000 | 1.000 (0.297 to 3.372) |
| L | 232 | 64.4% | 240 | 66.7% | L | 0.754 | 1.103 (0.597 to 2.041) |
| S | 128 | 35.6% | 120 | 33.3% | S | 0.754 | 0.906 (0.490 to 1.676) |
LL and SS: homozygous genotypes, LS: heterozygous genotype. L: long allele, S: short allele. Values of p≤0.05 were considered significant. OR (95% CI): Odd Ratio 95% confidence interval.
Distribution of biochemical and clinical variables according to 5-HTTLPR genotypes in diabetic patients
| 61.00±7.38 | 59.72±6.26 | 0.650 | |
| 136.38±6.51 | 151.63±14.02 | 0.013 | |
| 85.13±3.11 | 90.45±7.34 | 0.090 | |
| 30.83±0.96 | 28.73±2.24 | 0.029 | |
| 7.62±1.30 | 7.54±1.18 | 0.882 | |
| 233.88±61.80 | 237.71±59.73 | 0.885 | |
| 148.85±36.09 | 267.32±60.72 | <0.001 | |
| 190.52±20.74 | 300.51±56.01 | <0.001 | |
| 57.88±9.64 | 51.73±15.96 | 0.366 | |
| 103.26±23.57 | 195.93±55.04 | <0.001 | |
Data present as Mean±standard deviation and compared with t-test. Values of p≤0.05 were considered significant (which are bold*). SBP: Systolic Blood Pressure, DPB: Diastolic Blood Pressure, BMI: Body Mass Index, Hb: Hemoglobin, FBS: Fasting Blood Sugar, TG: Triglyceride, Chol: Cholesterol, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein.